Company Overview and News
In a filing with Bursa Malaysia yesterday, IT company Mexter said its wholly owned subsidiary - LYC Medicare Sdn Bhd (LYCM) - had entered into a service and collaboration agreement with UM’s University Malaya Medical Centre (UMMC) to establish the LYC Fertility Centre
BSMAF 1818 0075
KUALA LUMPUR (Oct 1): Based on corporate announcements and news flow today, companies in focus on Tuesday (Oct 2) may include: AppAsia Bhd, Bioalpha Holdings Bhd, Dataprep Holdings Bhd, E.A. Technique (M) Bhd, IHH Healthcare Bhd, Malaysia Airports Holdings Bhd, Mexter Technology Bhd, Prestariang Bhd, Sealink International Bhd, Taliworks Corp Bhd, Astro Malaysia Holdings Bhd and Telekom Malaysia Bhd.
6399 5014 5145 0075 2852 0179 4863 5225 8338 MYPRY MYTEF Q0F IHHHF
KUALA LUMPUR (Oct 1): Mexter Technology Bhd is collaborating with Universiti Malaya (UM) a to establish a brand to develop and market fertility and other medical services to high-end fertility patients, including inbound patients from overseas.
KUALA LUMPUR (July 5): Based on corporate announcements and news flow today, companies in focus on Wednesday (Sept 12) may include: IOI Properties Group Bhd, AirAsia Group Bhd, Bumi Armada Bhd, Country View Bhd, Chemical Company of Malaysia Bhd, Sunsuria Bhd, TDM Bhd, Serba Dinamik Holdings Bhd, TFP Solutions Bhd and Mexter Technology Bhd.
5249 0145 5049 BRDBF BSMAF 5210 0075 1818
KUALA LUMPUR (Sept 7): Mexter Technology Bhd is exiting the mobile services business due to the current challenging and increasingly saturated mobile services industry, as well as to stem further losses to the group.
BSMAF 0075 1818
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...